RNAC

Cartesian Therapeutics, Inc. (RNAC) | Rumor.io

Cartesian Therapeutics

RNAC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,700

Bullish sentiment (50-day avg)91%

Price to earnings ratio1.98

Market capitalization218.1M

Earnings per share-5.78

Dividend yield (TTM)—

Revenue (annual)2.8M

Net income (annual)-130.3M

Social

What share of all stock conversation is about RNAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 9

Cartesian Therapeutics, Inc. (RNAC) announced a licensing agreement with Westgene Biopharma for in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases, with undisclosed upfront and milestone payments.
The agreement combines WestGene's established targeted LNP platform with Cartesian's mRNA payload from Descartes-08, integrating two independently clinically tested technologies for rapid clinical translation.
Cartesian Therapeutics is planning to advance multiple next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding its mRNA payload portfolio, with a clinical trial expected to initiate in 2H 2026.

Generated by AI

Sentiment

Of the messages about RNAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	60.78% -20.1
Bearish	—	—	0% 0	39.22% +20.1

Bullish· Mar 22

$RNAC has significant upside potential, with a possible price target of $2.54.
The company's recent performance has been strong and steady, with a gap up to $1.86 and a potential run to the moon.
Analysts are optimistic about $RNAC, with a top price target of $4 and a strong buy signal, making it a good time to buy and push the stock to new heights.

Bearish· Mar 21

$RNAC is experiencing a sudden and unexpected drop, with some users attributing it to manipulation or a "pump and dump" scheme.
The price action is expected to continue downward, with some users hoping to see a return to the asset's all-time low (ATL).
The asset's recent news and results, including successful phase 3 trials and a strong cash position, have not been enough to sustain a rally, and some users are expressing disappointment and frustration.

Generated by AI

Topics

Of the messages about RNAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	96.5%
Technical Analysis	—	—	0%	2.33%
Analysts	—	—	0%	1%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.17%
Macro	—	—	0%	0%

Earnings· Nov 7

RNAC's parent company, Selecta Biosciences, Inc., is hosting a Q3 earnings call today at 8:30 AM Eastern.
The call will be streamed live and available on replay.
The call is scheduled for today at 8:30 AM Eastern, with an on-demand option available after.

Announcements· Jul 2

Cartesian Therapeutics announces positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis.
The company enters a $130M private placement equity financing, selling shares of common stock and Series B Non-Voting Convertible Preferred Stock at $20 per share.
Cartesian Therapeutics announces first patient dosed in Phase 2 trial of Descartes-08 in systematic lupus erythematosus, with the trial designed to evaluate safety and tolerability of outpatient administration without preconditioning chemotherapy.

Technical Analysis· Feb 3

RNAC is breaking out of a 7.5-month cup and handle pattern, with potential for significant price movement.
The breakout could result in a significant gap at the open, making it a potentially volatile trading situation.
Selling upside calls against some shares may be a strategy to manage risk and capitalize on potential gains.

Generated by AI

Community

Of the messages about RNAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	64.56%	23.34%
Newcomers	—	0%	35.44%	76.66%

Regulars· Jul 2

The Phase 2b trial of Descartes-08 in patients with myasthenia gravis showed positive topline results, with the company's stock price dropping 22% due to concerns about data interpretation and the lack of available data from the non-academic center cohort.
The company has announced a $130 million private placement equity financing, with insiders backstopping the deal at a 27% discount to the previous day's close, and Oppenheimer downgrading Cartesian Therapeutics from Outperform to Peer Perform.
The Phase 2 trial of Descartes-08 in systematic lupus erythematosus has started, with the first patient dosed, and the company's stock price has been affected by concerns about the quality of the data from the Phase 2b trial.

Newcomers· Feb 9

The newcomers are focused on the stock's potential for a pop due to its biotech concept, with one user accumulating a large position in anticipation of an inevitable increase.
The newcomers are interested in the recent surge in $RNAC and are trying to understand the underlying reasons for the stock's sudden rise, with one user speculating about sales bumps and DTC marketing.
The newcomers are monitoring the stock's price and are discussing their accumulation and entry points, with one user asking about the current interest in $SELB and its potential for a buy.

Generated by AI

FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On September 4, 2026, the Company issued to these employees options to purchase an aggregate of 59,700 shares of the Company’s common stock with an exercise price of $9.27, the closing trading price of the Company’s commo

22d agoYahoo! Finance Canada

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026One-on-one and group investor meetings at Morgan Stanley’s 24th Annual He

27d agoYahoo Finance

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading

1mo agoYahoo Finance

Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates

1mo agoInvesting.com

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027

1mo agoBarchart.com

Also Discussed

Investors talking about RNAC also mention

#	Name	Attention
1	SELB - Selecta Biosciences, Inc.	——
2	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0.01
3	ORTX - Orchard Therapeutics plc	——
4	Solid Biosciences Inc.SLDB	0.16%new
5	Vyne Therapeutics Inc.VYNE	0%0
6	BLCM - Bellicum Pharmaceuticals, Inc.	——
7	Ovid Therapeutics Inc.OVID	0%0
8	Clearside Biomedical Inc.CLSD	0%0
9	MORF - Morphic Holding, Inc.	——
10	Kazia Therapeutics Ltd Sponsored ADRKZIA	0%0

Cartesian Therapeutics, Inc.

Healthcare
Biotechnology

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s current pipeline centers on autologous CAR-T programs designed to modulate immune activity and address serious conditions such as generalized myasthenia gravis, systemic lupus erythematosus, and certain forms of myositis. Its lead candidate, Descartes-08, is being advanced across multiple autoimmune indications, while additional programs such as Descartes-15 and Descartes-33 expand the company’s research beyond its lead asset. Cartesian Therapeutics emphasizes engineered cell therapy and proprietary manufacturing capabilities to create targeted treatments that fit within the broader fields of immunology, cell therapy, and precision medicine. Headquartered in Frederick, Maryland, Cartesian Therapeutics plays a specialized role in the biotechnology market by focusing on advanced therapies for difficult-to-treat immune-mediated diseases.

Website

Location

7495 New Horizon Way

Frederick, MD, 21703

United States

Social

What share of all stock conversation is about RNAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 9

Cartesian Therapeutics, Inc. (RNAC) announced a licensing agreement with Westgene Biopharma for in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases, with undisclosed upfront and milestone payments.
The agreement combines WestGene's established targeted LNP platform with Cartesian's mRNA payload from Descartes-08, integrating two independently clinically tested technologies for rapid clinical translation.
Cartesian Therapeutics is planning to advance multiple next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding its mRNA payload portfolio, with a clinical trial expected to initiate in 2H 2026.

Generated by AI

Sentiment

Of the messages about RNAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	60.78% -20.1
Bearish	—	—	0% 0	39.22% +20.1

Bullish· Mar 22

$RNAC has significant upside potential, with a possible price target of $2.54.
The company's recent performance has been strong and steady, with a gap up to $1.86 and a potential run to the moon.
Analysts are optimistic about $RNAC, with a top price target of $4 and a strong buy signal, making it a good time to buy and push the stock to new heights.

Bearish· Mar 21

$RNAC is experiencing a sudden and unexpected drop, with some users attributing it to manipulation or a "pump and dump" scheme.
The price action is expected to continue downward, with some users hoping to see a return to the asset's all-time low (ATL).
The asset's recent news and results, including successful phase 3 trials and a strong cash position, have not been enough to sustain a rally, and some users are expressing disappointment and frustration.

Generated by AI

Topics

Of the messages about RNAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	96.5%
Technical Analysis	—	—	0%	2.33%
Analysts	—	—	0%	1%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.17%
Macro	—	—	0%	0%

Earnings· Nov 7

RNAC's parent company, Selecta Biosciences, Inc., is hosting a Q3 earnings call today at 8:30 AM Eastern.
The call will be streamed live and available on replay.
The call is scheduled for today at 8:30 AM Eastern, with an on-demand option available after.

Announcements· Jul 2

Cartesian Therapeutics announces positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis.
The company enters a $130M private placement equity financing, selling shares of common stock and Series B Non-Voting Convertible Preferred Stock at $20 per share.
Cartesian Therapeutics announces first patient dosed in Phase 2 trial of Descartes-08 in systematic lupus erythematosus, with the trial designed to evaluate safety and tolerability of outpatient administration without preconditioning chemotherapy.

Technical Analysis· Feb 3

RNAC is breaking out of a 7.5-month cup and handle pattern, with potential for significant price movement.
The breakout could result in a significant gap at the open, making it a potentially volatile trading situation.
Selling upside calls against some shares may be a strategy to manage risk and capitalize on potential gains.

Generated by AI

Community

Of the messages about RNAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	64.56%	23.34%
Newcomers	—	0%	35.44%	76.66%

Regulars· Jul 2

The Phase 2b trial of Descartes-08 in patients with myasthenia gravis showed positive topline results, with the company's stock price dropping 22% due to concerns about data interpretation and the lack of available data from the non-academic center cohort.
The company has announced a $130 million private placement equity financing, with insiders backstopping the deal at a 27% discount to the previous day's close, and Oppenheimer downgrading Cartesian Therapeutics from Outperform to Peer Perform.
The Phase 2 trial of Descartes-08 in systematic lupus erythematosus has started, with the first patient dosed, and the company's stock price has been affected by concerns about the quality of the data from the Phase 2b trial.

Newcomers· Feb 9

The newcomers are focused on the stock's potential for a pop due to its biotech concept, with one user accumulating a large position in anticipation of an inevitable increase.
The newcomers are interested in the recent surge in $RNAC and are trying to understand the underlying reasons for the stock's sudden rise, with one user speculating about sales bumps and DTC marketing.
The newcomers are monitoring the stock's price and are discussing their accumulation and entry points, with one user asking about the current interest in $SELB and its potential for a buy.

Generated by AI

Cartesian Therapeutics

Social

Jun 9

Bullish· Mar 22

Bearish· Mar 21

Earnings· Nov 7

Announcements· Jul 2

Technical Analysis· Feb 3

Regulars· Jul 2

Newcomers· Feb 9

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Cartesian Therapeutics, Inc.

Company Information

Location

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Social

Jun 9

Bullish· Mar 22

Bearish· Mar 21

Earnings· Nov 7

Announcements· Jul 2

Technical Analysis· Feb 3

Regulars· Jul 2

Newcomers· Feb 9